Developing a new treatment to protect against radiation damage
Official title: DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE
Funded at Ceramedix Holding, LLC · NIH-11118646 · Data updated 2026-11-12
This study is testing a new treatment called CX-01 that aims to protect blood vessels from damage caused by radiation, which could help people who have been exposed to harmful radiation avoid serious health issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ceramedix Holding, LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,427,108 |
| NIH project number | 75N93023C00015-P00003-9999-1 |
| Project ID | NIH-11118646 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals at risk of radiation exposure, such as those involved in nuclear accidents or certain medical treatments.
✕Less likely to help
Patients who have not been exposed to radiation or those with pre-existing severe gastrointestinal conditions may not benefit from this research.
What this research studies
This research focuses on creating a new medical countermeasure called CX-01, which aims to prevent damage caused by radiation exposure, particularly to the microvascular system. By targeting the early stages of radiation injury, CX-01 seeks to inhibit cell death in the blood vessels, which can lead to severe gastrointestinal complications. The research involves extensive animal studies to model the effects of radiation and test the effectiveness of this novel treatment. If successful, this could provide a critical solution for individuals exposed to harmful radiation.
Why it matters
Potential benefit: If successful, this research could offer a groundbreaking treatment option for patients suffering from acute radiation syndrome.
How similar studies have gone: While there is ongoing research in radiation countermeasures, the specific approach of CX-01 is novel and has not been previously tested in this context.
Where this research is happening
-
Ceramedix Holding, LLC
New York, United States Active
Researchers
- Principal investigator: Dimmler Iii, Charles — Ceramedix Holding, LLC
- Study coordinator: Dimmler Iii, Charles
Related research
Other NIH-funded projects on the same topics.
-
Gas Marble therapy to protect skin after radiation exposure
This grant tests a new gas-based treatment delivered as gas marbles to help skin recover after radiation damage.
-
A drug that helps repair DNA after radiation exposure
A new drug candidate aims to help the body repair damaged DNA after accidental or wartime radiation exposure to reduce organ injury and death.
-
Non-invasive skin biomarkers for radiation exposure
A study to find and measure skin biomarkers that indicate radiation exposure using a painless tape-stripping method on skin.
-
Restoring bone marrow blood vessels to prevent delayed radiation damage
This project aims to help people exposed to acute radiation by repairing the bone marrow’s blood vessel network to support healthier blood cell recovery over time.
-
Raman-based quick triage for radiation exposure
A new approach uses Raman spectroscopy and AI to quickly estimate radiation dose in people exposed to a radiological event, helping doctors decide who needs urgent treatment.
-
ACE2-agonist to reduce long-term radiation damage after ARS
Aims to test an ACE2-activating drug (diminazene aceturate) to lessen long-term organ damage after acute radiation exposure in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.